Skip to main content
    • Aa
    • Aa
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 2
  • Cited by
    This article has been cited by the following publications. This list is generated based on data provided by CrossRef.

    McElroy, Heather J. Roberts, Stuart K. Thompson, Alex J. Angus, Peter W. McKenna, Sarah Jane Warren, Emma and Musgrave, Sharon 2016. Medical resource utilization and costs among Australian patients with genotype 1 chronic hepatitis C: results of a retrospective observational study. Journal of Medical Economics, p. 1.

    Daw, Mohamed A. Dau, Aghynya A. and Agnan, Mohamed M. 2012. Influence of Healthcare-Associated Factors on the Efficacy of Hepatitis C Therapy. The Scientific World Journal, Vol. 2012, p. 1.

  • International Journal of Technology Assessment in Health Care, Volume 28, Issue 4
  • October 2012, pp. 398-406


  • Debbie Hartwell (a1), Jeremy Jones (a2), Louise Baxter (a2) and Jonathan Shepherd (a2)
  • DOI:
  • Published online: 01 September 2012

Background: Peginterferon alfa and ribavirin combination therapy is an effective treatment for many patients with chronic hepatitis C virus (HCV). Reducing the length of treatment may be advantageous. We performed a systematic review and economic evaluation to assess shorter treatment duration of this regimen.

Methods: We searched fourteen bibliographic databases (including The Cochrane Library, Medline, and Embase) from 2000 to October 2009 and consulted experts and drug manufacturers. Eligible articles were randomized controlled trials (RCTs) selected according to predefined criteria. We undertook an economic evaluation to assess the cost-effectiveness of shortened treatment versus standard treatment in the UK.

Results: Six trials were included. In the sub-group of patients who had low viral load (LVL) and a rapid virological response (RVR), there were no statistically significant differences in sustained virological response (SVR) rates between patients who received standard treatment (range, 83 percent to 100 percent) and those who received shortened courses (range 84 percent to 96 percent) (24 weeks for genotype 1, 16 weeks for genotype 2/3). Shortened treatment resulted in cost savings, but in some scenarios also resulted in poorer outcome, compared with standard treatment. This requires a judgment to be made on the value of the quality-adjusted life-year loss resulting from adopting a shorter treatment regimen, if shorter treatment is associated with a lower SVR than standard treatment duration.

Conclusions: For chronic HCV patients who have LVL and achieve an RVR, shortened peginterferon and ribavirin combination therapy could be considered as a viable treatment option.

Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

1.T Berg , V Weich , G Teuber , et al.Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1-infected patients. Hepatology. 2009;50:369377.

3.L. Curtis Unit costs of health and social care. Canterbury: Personal Social Services Research Unit, University of Kent; 2008.

6.GR Foster , RD Goldin , J Main , et al.Management of chronic hepatitis C: Clinical audit of biopsy based management algorithm. BMJ. 1997;315:453458.

7.MG Ghany , DB Strader , DL Thomas , LB Seeff . Diagnosis, management, and treatment of Hepatitis C: An update. Hepatology. 2009;49:13351374.

8.D Hartwell , J Jones , L Baxter , J Shepherd . Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: A systematic review and economic evaluation. Health Technol Assess. 2011;15:1204.

9.D Hartwell , J Shepherd . Pegylated and non-pegylated interferon-alfa and ribavirin for the treatment of mild chronic hepatitis C: A systematic review and meta-analysis. Int J Technol Assess Health Care. 2009;25:5662.

10.JPT Higgins , DT Altman . Assessing risk of bias in included studies. In: JPT Higgins , DT Altman , eds. Cochrane handbook for systematic reviews of interventions. Version 5.0.1 (updated September 2008). The Cochrane Collaboration; 2008.

11.C-H Liu , C-J Liu , C Lin , et al.Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: A multicenter, randomized controlled trial. Clin Infect Dis. 2008;47:12601269.

13.A Mangia , N Minerva , D Bacca , et al.Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial. Hepatology. 2008;47:4350.

14.AH Mohsen , Trent HCV Study Group. The epidemiology of hepatitis C in a UK health regional population of 5.12 million. Gut. 2001;48:707713.

20.J Shepherd , J Jones , D Hartwell , et al.Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: A systematic review and economic evaluation. Health Technol Assess. 2007;11:1205.

21.AA Stinnett , J Mullahy . Net health benefits: A new framework for the analysis of uncertainty in cost effectiveness analysis. Med Decis Making. 2009;18:S68S80.

23.The Global Burden Of Hepatitis C Working Group. Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol. 2004;44:2029.

24.BJ Thomson , RG Finch . Hepatitis C virus infection. Clin Microbiol Infect. 2005;11:8694.

25.M von Wagner , M Huber , T Berg , et al.Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology. 2005;129:522527.

26.M Wright , R Grieve , J Roberts , et al.Health benefits of antiviral therapy for mild chronic hepatitis C: Randomised controlled trial and economic evaluation. Health Technol Assess. 2006;10:1113.

27.M Yu , C Dai , J Huang , et al.Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: A randomized trial. Hepatology. 2008;47:18841893.

28.M Yu , C Dai , J Huang , et al.A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut. 2007;56:553559.

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

International Journal of Technology Assessment in Health Care
  • ISSN: 0266-4623
  • EISSN: 1471-6348
  • URL: /core/journals/international-journal-of-technology-assessment-in-health-care
Please enter your name
Please enter a valid email address
Who would you like to send this to? *